The work was performed at the Purdue University School of Veterinary Medicine. This work was presented as an oral scientific abstract at the Veterinary Cancer Society Annual Scientific Meeting, 2010, Anaheim, California.
Clinical Trial of Vinblastine in Dogs with Transitional Cell Carcinoma of the Urinary Bladder
Version of Record online: 13 SEP 2011
Copyright © 2011 by the American College of Veterinary Internal Medicine
Journal of Veterinary Internal Medicine
Volume 25, Issue 6, pages 1385–1390, November-December 2011
How to Cite
Arnold, E.J., Childress, M.O., Fourez, L.M., Tan, K.M., Stewart, J.C., Bonney, P.L. and Knapp, D.W. (2011), Clinical Trial of Vinblastine in Dogs with Transitional Cell Carcinoma of the Urinary Bladder. Journal of Veterinary Internal Medicine, 25: 1385–1390. doi: 10.1111/j.1939-1676.2011.00796.x
- Issue online: 16 NOV 2011
- Version of Record online: 13 SEP 2011
- Manuscript Accepted: 4 AUG 2011
- Manuscript Revised: 6 JUL 2011
- Manuscript Received: 2 FEB 2011
Transitional cell carcinoma (TCC) of the urinary bladder of dogs can be a difficult cancer to treat, and effective therapies are limited. Vinblastine has been used in humans with TCC and has potent anti-proliferative effects against canine TCC cells in vitro.
To determine the antitumor activity and toxicoses of vinblastine in dogs with urinary bladder TCC.
Animals selected were 28 privately owned dogs that presented to the Purdue University Veterinary Teaching Hospital (PUVTH) with measurable, histologically confirmed TCC.
Prospective clinical trial: The starting vinblastine dosage was 3.0 mg/m2IV every 2 weeks. Treatment continued until cancer progression or unacceptable toxicoses occurred. Complete evaluations (physical exam, complete blood count [CBC], serum biochemical profile, urinalysis, thoracic radiography, abdominal ultrasound [US]) were performed at 8-week intervals. Urinary tract US with bladder tumor mapping was performed monthly. Toxicoses were graded according to Veterinary Co-Operative Oncology Group (VCOG) criteria.
Tumor responses included 10 (36%) partial remission, 14 (50%) stable disease, and 4 (14%) progressive disease. The median progression free interval was 122 days (range, 28–399 days). The median survival time was 147 days (range, 28–476 days) from 1st vinblastine treatment to death and 299 days (range, 43–921 days) from diagnosis to death. The majority of dogs (27 of 28) did not have clinically relevant adverse effects. Seventeen of 28 (61%) dogs required dosage reductions because of neutropenia.
Conclusion and Clinical Importance
Vinblastine has antitumor activity against TCC in dogs and can be considered another treatment option for this cancer.